tirzepatide and bone loss Tirzepatide: A Promising Drug for Type 2 Diabetes Beyond Effects of Semaglutide and Tirzepatide

#Pharmacology #Semaglutide #GLP1 #DiabetesManagement #ObesityTreatment #PharmaEducation #ClinicalPharmacology #PharmaceuticalScience #DrugMechanism #HealthcareInnovation #PharmaStudents #MedicalScience Semaglutide: GLP-1 Receptor Agonist for Diabetes and Obesity "Semaglutide" Class GLP-1 Receptor Agonist (Glucagon-Like Peptide-1 analogue) Mechanism of Action (MOA) Mimics endogenous GLP-1 hormone Stimulates glucose-dependent insulin secretion from pancreatic -cells Suppresses glucagon release from -cells Delays gastric emptying prolonged satiety Acts on hypothalamic appetite centers reduced food intake Result: Improved glycemic control + significant weight reduction Approved Uses Type 2 Diabetes Mellitus improves glycemic control Chronic Weight Management (obesity / overweight with comorbidities) Reduction of cardiovascular risk in T2DM patients with established CVD Contraindications Personal or family history of Medullary Thyroid Carcinoma (MTC) Multiple Endocrine Neoplasia Syndrome type 2 (MEN2) Known hypersensitivity to semaglutide Caution in patients with history of pancreatitis Use in Pregnancy Not recommended during pregnancy Animal studies show potential fetal harm and weight-loss drugs are generally avoided in pregnancy

Why can this medication give my breath or sweat a fishy smell

Administration of GEP44 resulted in potent anorectic effects in two-to-five-day treatment studies in both lean and diet-induced obese (DIO) rats

The one that has most captured public attention

Most people start to see real changes after about 12 weeks

Tirzepatide tends to produce more weight loss but costs more